In a phase I/II trial evaluating gavocabtagene autoleucel, a T-cell receptor (TCR) fusion construct targeting MSLN, patients with MSLN-expressing solid tumors, including mesothelioma and ovarian cancer, demonstrated encouraging antitumor responses. This evidence concerns the gene MSLN and ovarian carcinoma.